← Back to Search

Vitamin

Nicotinamide riboside for Small Fiber Neuropathy

Phase 2
Waitlist Available
Led By Ahmet Hoke
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Study Summary

This trial will test if a nutritional supplement can prevent nerve degeneration and aid in nerve regeneration.

Eligible Conditions
  • Small Fiber Neuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Skin
Skin

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nicotinamide RibosideExperimental Treatment1 Intervention
Experimental group of participants will receive Nicotinamide riboside at a dose of 900 mg twice a day orally.
Group II: PlaceboPlacebo Group1 Intervention
Study participants in the placebo arm will receive placebo pills that are similar in size and shape to the experimental group drug.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
2021
Completed Phase 3
~400

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,256 Previous Clinical Trials
14,820,021 Total Patients Enrolled
2 Trials studying Small Fiber Neuropathy
11 Patients Enrolled for Small Fiber Neuropathy
Adelson Medical Research FoundationUNKNOWN
Ahmet HokePrincipal InvestigatorJohns Hopkins University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any ineligibility factors for this particular clinical trial?

"The ideal candidate for this research study is somebody between 18-65 years old, with a body mass index below 32. They must also have small fiber neuropathy and a normal neurological examination (as defined by a Neuropathy Impairment Score lower than 2)."

Answered by AI

Does this experiment only apply to young people, or are older individuals also being seen?

"The age range for potential participants in this clinical trial is 18 to 65."

Answered by AI

Are we able to register for this opportunity now?

"Yes, as indicated by the clinicaltrials.gov website, this study is still recruiting patients. The trial was originally posted on September 1st 2020 and has been updated June 14th of this year. Presently, the research team is looking for 40 individuals willing to participate at a single location."

Answered by AI

Has Nicotinamide riboside been cleared by the FDA?

"While there is some evidence that indicates nicotinamide riboside may be safe, it only received a score of 2 because, as a Phase 2 trial medication, no efficacy data exists yet."

Answered by AI

Are there any previous case studies of Nicotinamide riboside's efficacy?

"There are currently 16 clinical trials underway for Nicotinamide riboside, with 1 in Phase 3. Notably, there are several studies taking place in Winston-Salem, North carolina; though 20 locations total are running trials for Nicotinamide riboside."

Answered by AI

How many people are currently signed up to participate in this research?

"That is correct, the listing on clinicaltrials.gov does state that this research study is recruiting patients as of now. The first posting was on September 1st 2020 with the most recent update being on June 14th 2022. They are looking for a total of 40 people to participate at 1 location."

Answered by AI

Who else is applying?

What state do they live in?
Oregon
Massachusetts
How old are they?
18 - 65
What site did they apply to?
Johns Hopkins Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0

How responsive is this trial?

Most responsive sites:
  1. Johns Hopkins Hospital: < 24 hours
Typically responds via
Email
Average response time
  • < 1 Day
Recent research and studies
clinicaltrials.govStudy
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
2020. "Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03912220.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top